How India Exports Erythromycin to the World

Erythromycin has a longstanding presence in the U.S. market, with multiple approved Abbreviated New Drug Applications (ANDAs). For instance, the FDA approved a generic version of Eryc (erythromycin delayed-release capsules) by Pharmobedient on December 22, 1986. Similarly, a generic version of Erythrocin (erythromycin lactobionate for injection) was approved for Hospira on October 31, 1986. These approvals indicate a well-established regulatory pathway for erythromycin products in the U.S. Given the presence of 368 active Indian exporters, it is crucial for these entities to ensure compliance with FDA regulations, including adherence to current Good Manufacturing Practices (cGMP) and maintaining up-to-date Drug Master Files (DMFs).

In the European Union, erythromycin is subject to marketing authorization requirements overseen by the European Medicines Agency (EMA). A notable regulatory action includes the Periodic Safety Update Report Single Assessment (PSUSA) for erythromycin (systemic use), identified as PSUSA/00010808/202203, with conclusions published on January 10, 2023. This assessment underscores the importance of ongoing pharmacovigilance and compliance with EU Good Manufacturing Practice (GMP) standards for Indian exporters targeting the EU market.

Erythromycin is listed in the 24th edition of the WHO Model List of Essential Medicines, published on September 5, 2025. This inclusion highlights its critical role in treating priority health conditions globally. The WHO Model List serves as a guide for countries to develop and update their national essential medicines lists, ensuring the availability of effective and safe medicines. Additionally, erythromycin is recognized in various pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), reflecting its established quality standards.

In India, erythromycin is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) sets ceiling prices for essential medicines; however, specific ceiling prices for erythromycin should be verified with the latest NPPA notifications. For exports, Indian pharmaceutical companies must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with national regulations and facilitating international trade.

The primary patents for erythromycin have long expired, allowing for robust generic competition. This competitive landscape is evident from the numerous generic versions approved by regulatory agencies worldwide, including the FDA and EMA. Indian exporters benefit from this scenario, as they can produce and export erythromycin without infringing on active patents, provided they adhere to the regulatory requirements of the importing countries.

In February 2026, the UK Veterinary Medicines Directorate (VMD) released data indicating a significant decline in erythromycin sales for veterinary use, with the last reported sales in 2017. This trend may influence the demand for erythromycin in veterinary applications. Additionally, the WHO published the 24th edition of the Model List of Essential Medicines in September 2025, reaffirming erythromycin's status as an essential medicine. These developments underscore the importance of staying informed about regulatory changes and market dynamics to maintain a competitive edge in the global pharmaceutical industry.

India's pharmaceutical industry, including the production of Erythromycin, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. Approximately 60–70% of India's API and KSM requirements are sourced from China, creating a significant supply chain vulnerability. This dependency exposes the industry to risks associated with geopolitical tensions, trade disputes, and potential disruptions in the supply chain.

To mitigate these risks, the Indian government has implemented the Production Linked Incentive (PLI) Scheme for Bulk Drugs, aiming to promote domestic manufacturing of critical KSMs, DIs, and APIs. As of September 2025, the scheme has led to the establishment of manufacturing capacities for 26 KSMs and APIs, resulting in cumulative sales of ₹2,315 crore and avoiding imports worth ₹1,807 crore. Despite these efforts, the transition to self-reliance is ongoing, and the industry remains susceptible to external supply chain disruptions.

The export market for Erythromycin from India is notably concentrated, with the top five exporters accounting for 48.9% of total exports. MEDOPHARM leads with a 32.0% share, followed by BDH INDUSTRIES LIMITED (7.1%), LINCOLN PHARMACEUTICALS LTD (3.6%), S KANT HEALTHCARE LIMITED (3.5%), and MEDREICH LIMITED (2.7%). This concentration poses a single-source risk, as disruptions affecting these key players could significantly impact the global supply of Erythromycin.

The PLI Scheme for Pharmaceuticals, launched in March 2021, aims to enhance India's manufacturing capabilities and reduce import dependency. By September 2025, the scheme had attracted a cumulative investment of ₹40,890 crore, surpassing the initial commitment of ₹17,275 crore. While this initiative is strengthening the domestic pharmaceutical sector, the current supplier concentration in Erythromycin exports remains a concern.

Global shipping routes, including the Red Sea and the Strait of Hormuz, are critical for the transportation of pharmaceutical products. Any geopolitical tensions or conflicts in these regions can lead to shipping delays, increased costs, and supply chain disruptions. Additionally, ongoing US-China trade tensions have the potential to affect the availability and pricing of APIs and KSMs sourced from China, further impacting India's pharmaceutical exports.

Regulatory bodies such as the FDA and EMA have issued shortage alerts for various antibiotics in recent years, highlighting the fragility of global pharmaceutical supply chains. While specific alerts for Erythromycin have not been prominent, the interconnected nature of the industry means that disruptions in related sectors can have cascading effects.

• Diversify API and KSM Sources: Encourage the development of alternative suppliers in different regions to reduce dependency on a single country.

• Strengthen Domestic Manufacturing: Accelerate the implementation of the PLI Scheme to boost local production capacities for critical APIs and KSMs.

• Expand Exporter Base: Support smaller pharmaceutical companies to enter the export market, thereby reducing supplier concentration.

• Enhance Supply Chain Monitoring: Implement advanced tracking systems to identify and address potential disruptions in real-time.

• Develop Contingency Plans: Establish strategic reserves and alternative logistics arrangements to mitigate the impact of geopolitical and shipping disruptions.

RISK_LEVEL: MEDIUM